title: Multicenter, double-blind, placebo-controlled trial of triamcinolone acetonide nasal aerosol in the treatment of perennial allergic rhinitis.
abstract: In a double-blind study involving 205 patients with perennial allergic rhinitis, statistically significantly greater symptomatic improvements were evident following the administration of 200 micrograms/day triamcinolone acetonide aerosol than following placebo. These improvements were evident as early as week 1 and were sustained throughout the 12-week study. They were accompanied by greater reductions in nasal eosinophils. Triamcinolone acetonide aerosol was well tolerated and had no effect on serum cortisol levels.
authors.affiliation: Department of Clinical Research, Rorer Central Research, Horsham, PA 19044.
authors.forename: S
authors.initials: S
authors.lastname: Spector
authors.forename: E
authors.initials: E
authors.lastname: Bronsky
authors.forename: P
authors.initials: P
authors.lastname: Chervinsky
authors.forename: G
authors.initials: G
authors.lastname: Lotner
authors.forename: J
authors.initials: J
authors.lastname: Koepke
authors.forename: J
authors.initials: J
authors.lastname: Selner
authors.forename: D
authors.initials: D
authors.lastname: Pearlman
authors.forename: D
authors.initials: D
authors.lastname: Tinkelman
authors.forename: S
authors.initials: S
authors.lastname: Weakley
authors.forename: V
authors.initials: V
authors.lastname: Alderfer
mesh_terms: D000281:Administration, Intranasal; D000336:Aerosols; D004311:Double-Blind Method; D006801:Humans; D015337:Multicenter Studies as Topic; D010919:Placebos; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000503:physiopathology; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000336:Aerosols; D010919:Placebos; D014222:Triamcinolone Acetonide